Sio Gene Therapies
Sio Gene Therapies is a clinical-stage biopharmaceutical company.
Business Model:
Revenue: $0
Employees: 2-10
Industries / Tags:
Detailed Sio Gene Therapies Information
Geographic Data
Address: 130 West 42nd Street
City: New York
State: NY
Zip: 10036
Country: US
Financial Info
Stage:
post ipo equity
Raised Last:
$75M
Raised Total:$130M
Social
Metrics
2,375,605Website Global Rank
7,745Website Monthly Traffic
Twitter Followers
Description
Sio Gene Therapies, formerly known as Axovant, is a clinical-stage company with a singular focus on pushing the boundaries of gene therapy to develop treatments for debilitating neurodegenerative diseases, including GM1 gangliosidosis, Tay-Sachs/Sandhoff disease, and Parkinson’s disease. Sio is leveraging its foundational scientific expertise built on decades of research, extensive collaborations with leading gene therapy institutes, and a flexible vector platform to liberate patients with debilitating diseases through the transformational power of gene therapies.
Contact Phone:
Contact Email:
Sio Gene Therapies went public on 6/12/2015 on the NASDAQ
Listed Exchange:
NASDAQ
IPO Date:
6/12/2015
Ticker Symbol:
SIOX
Live
Opened: -/share
| EBITDA | - |
| Total Cash | - |
| Total Debt | - |
| Total Revenue | - |
| Total Profit (Gross) | - |
| PE Ratio | - |
| Announced Date | Company | Transaction | Money Raised |
|---|
| Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 2/2017 | Post-IPO Debt | 1 | $55M |
Hercules Capital Hercules Capital |
2/2020 | Post-IPO Equity | $74.7M | 6/2015 | IPO | $315M |
|---|
| Announced Date | Name | Price |
|---|
Employee Departments
Employee States
|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|
